According to University of Alabama researchers, Curcumin was found to decrease the mRNA and protein expression of the oncoprotein MDM2 and enhance the expression of tumor modulator p21.

Bioponic Phytoceuticals reported that Curecumin™, a Bioresonant Phytotherapeutic® form of Turmeric-containing curcumin, may be an important treatment for prostate cancer.


In the March 1 issue of Cancer Research, scientists from the Comprehensive Cancer Center of the University of Alabama report on a study designed to elucidate the molecular anticancer effect of curcumin in a preclinical prostate cancer model. Curcumin was found to decrease the mRNA and protein expression of the oncoprotein MDM2 and to enhance the expression of tumor modulator p21.

Previous articleFirst Treatment for PNH Approved
Next articleAtheroGenics’ Shares Sink after a Disappointing Phase III for Atherosclerosis Drug